-2.46%
Today
Loading 1D prices…
Company profile
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Naples, FL, United States
Employees
4
Fiscal year end
1231
CIK
1896212
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US Inc. Common Stock | $2.6M | $0.00 | — | -$0.55 | -2.44% | Unrated |
| SPRCSciSparc Ltd. Ordinary Shares | $2.7M | $856K | -1422.78% | $203.89 | -1.68% | Unrated |
| GNPXGenprex Inc. Common Stock | $2.7M | $0.00 | — | -$382.80 | +3.02% | Unrated |
| PPBTPurple Biotech Ltd. American Depositary Shares | $2.5M | $0.00 | — | -$54.00 | -11.05% | Buy |
| ONCOOnconetix Inc. Common Stock | $2.9M | $815.4K | -1720.98% | -$16.56 | +2.79% | Unrated |